PT -期刊文章盟-格雷戈里天盟法蒂玛Amtashar盟梅兰妮Yarbrough AU -彼得Koertvelyessy盟哈拉尔德Pruss AU -罗伯特Bucelli盟马文fritzl AU -沃伦·梅森AU -大卫Tang-Wai AU -克劳德Steriade AU -朱利安赫伯特盟伊丽莎白掠夺非盟-杰克Ladenson AU -约翰·c·莫里斯AU -安妮·费根TI -量化脑脊液神经损伤的生物标志物,在抗体介入神经炎症和突触完整脑炎(p2.2 - 001) DP - 2019年4月09年TA -神经病学第六PG - p2.2 - 001 - 92 IP - 15补充4099 - //www.ez-admanager.com/content/92/15_supplement/p2.2 001. - 001.短4100 - //www.ez-admanager.com/content/92/15_supplement/p2.2 - -全所以Neurology2019 4月09年;首页92 AB -目的:测量脑脊液(CSF)神经损伤的生物标志物,神经炎症和突触完整抗体介入脑炎患者(AME)。背景:恢复AME患者经常表现出持久的损害在内存和执行功能。生物标志物,通知贡献者长期认知后遗症需要识别高危病人的长期赤字。设计/方法:收集脑脊液从46名患者在诊断时NMDAR (n = 35)或LGI1 / CASPR-2 (n = 11) AME, 40岁,gender-similar认知正常志愿者评估在圣路易斯华盛顿大学(美国);多伦多大学,有丝分裂原诊断/卡尔加里大学(加拿大);或者查利特医院以及大学医院马格德堡(德国)。神经损伤的生物标志物(总τ,VILIP-1),炎症(YKL-40)和突触完整(neurogranin SNAP-25)病人和对照组之间比较,控制年龄(单变量ANCOVA)。结果:NMDAR脑炎患者年轻(平均26年;范围内,4.0 - -41.8)比患者LGI1 / CASPR2 AME(70.4年,60.6 - -83.2;术中,0.001)。神经损伤的标志相似(平均总τ(95%置信区间):22.4 pg / ml (16.3 - -28.5); vs. 20.2 pg/ml [13.7–26.8]; p=0.63) or decreased (VILIP-1: 42.5 pg/ml [31.4–53.6]; vs. 119.0 pg/ml [107.0–130.9]; p<0.001) in patients versus controls. The neuroinflammatory biomarker YKL-40 was elevated in patients compared to controls (YKL-40: 303.0 pg/ml [257.1–348.9] vs. 162.1 ng/ml [113.4–210.8]; p<0.001), while markers of synaptic integrity were decreased (SNAP-25: 1.54 pg/ml [1.19–1.89] vs. 3.20 pg/ml [2.83–3.58], p<0.001; neurogranin: 577.5 pg/ml [336.3–818.7] vs. 1462.9 pg/ml [1204.2–1721.7]; p<0.001). VILIP-1 levels differentiated patients with NMDAR (27.0 pg/ml [12.9–41.1]) from LGI1/CASPR2 AME (84.5 pg/ml [47.1–121.8]; p=0.02). No other biomarker differences were observed between patients.Conclusions: Cerebrospinal fluid biomarkers suggest that neuronal integrity is acutely maintained in AME patients. Low-levels of biomarkers of synaptic integrity may reflect antibody-mediated internalization of cell-surface receptors, and may represent an acute correlate of antibody-mediated synaptic dysfunction underlying cognitive sequelae in recovering patients.Disclosure: Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed (EBSCO Health).Dr. Day holds stock and/or stock options in ANI Pharmaceuticals. Dr. Amtashar has nothing to disclose. Dr. Yarbrough has nothing to disclose. Dr. Körtvelyessy has nothing to disclose. Dr. Pruss has nothing to disclose. Dr. Bucelli has nothing to disclose. Dr. Fritzler has nothing to disclose. Dr. Mason has nothing to disclose. Dr. Tang-Wai has nothing to disclose. Dr. Steriade has nothing to disclose. Dr. Hebert has nothing to disclose. Dr. Herries has nothing to disclose. Dr. Ladenson has nothing to disclose. Dr. Morris has received research support from Eli Lilly and Biogen. Dr. Fagan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Diagnostics, IBL International, AbbVie, Biogen, DiamiR, LabCorp and Araclon Biotech/Griffols.